Ozempic, the blockbuster GLP-1 drug that was originally approved to treat type 2 diabetes, has now also been approved by the ...

The U.S. FDA has approved Novo Nordisk's Ozempic for reducing the risk of kidney failure and disease progression, as well as ...

Ozempic’s expanded approval in the U.S. could transform how doctors treat patients with the condition, which involves a ...

The Food and Drug Administration approved Novo Nordisk’s Ozempic as the first GLP-1 treatment option for people with type 2 ...

Ozempic, or semaglutide, can now be used to reduce the risk of worsening kidney disease or kidney failure in adults with type ...

Regulators have approved the drug as a treatment for weight loss, Type 2 diabetes and lowering the risk of heart attacks and ...

Novo Nordisk said on Tuesday the U.S. FDA has approved its blockbuster drug Ozempic to lower the risk of progression of ...

The approval adds a new indication for GLP-1 drugs and gives Novo an advantage over Lilly’s rival diabetes drug Mounjaro, ...

The FDA’s approval of Ozempic to battle chronic kidney disease “allows us to more broadly address conditions within cardiovascular-kidney-metabolic syndrome, which affects millions of ...

The FDA on Tuesday approves Ozempic, the weight loss drug made by Novo Nordisk, for the treatment of chronic kidney disease ...

A popular diabetes drug just got a major new approval—and it could be a game-changer for millions of Americans at risk for ...